Literature DB >> 26741787

Measuring Patients' Knowledge About Adverse Effects of Angiotensin-Converting Enzyme Inhibitors.

Slobodan M Jankovic1, Milica Dajic, Sasa Jacovic, Sanja Markovic, Tatjana Papic, Tamara Petrusic, Milica Radojkovic, Anica Rankovic, Marko Tanaskovic, Marko Vasic, Dusan Vukicevic, Radica Zivkovic Zaric, Marina Kostic.   

Abstract

BACKGROUND: Knowledge about adverse effects of medications is an important part of proper medication use and prerequisite for good treatment adherence.
OBJECTIVE: The aim of our study was to construct, develop, and test a new questionnaire for the measurement of patients' knowledge about adverse drug reactions of angiotensin-converting enzyme (ACE) inhibitors.
METHODS: The 8-item questionnaire was constructed to measure adverse reactions to ACE inhibitors. The questions were closed, with 7 offered answers, in the form of a Likert scale. It was tested for psychometric properties on patients who visited their general practitioners at state-owned health facilities in 5 Serbian cities: Belgrade, Kragujevac, Banja Luka, Gracanica, and Despotovac.
RESULTS: The questionnaire was tested on 259 patients from general practice, taking an ACE inhibitor for more than 3 months. Experience with at least 1 adverse effect of ACE inhibitor was reported in 64 patients (24.7%), only 94 patients (36.3%) previously received any form of information about at least 1 adverse effect of ACE inhibitors from health workers, and only 42% expressed knowledge of any adverse events. The patients who were informed knew about the following adverse events as phrased in the official patient information leaflets: severe dizziness or light-headedness (44%); cough (37%); swelling of the hands, face, lips, or tongue (32%); indigestion (22%); headache (51%); and difficulty in breathing (15%). The questionnaire showed satisfactory internal consistency, with Cronbach α of 0.767, and individual scores correlated with general education of the patients. Factorial analysis revealed 2 domains (subscales): the first one with 5 questions is directed to adverse effects the patients may physically experience directly, whereas the second with 3 questions measures knowledge about adverse effects that could be experienced only indirectly, through conditions caused by the adverse effects.
CONCLUSIONS: The questionnaire about knowledge of ACE inhibitors' adverse effects is a reliable and probably valid instrument for measuring patients' knowledge about adverse effects of ACE inhibitors.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 26741787     DOI: 10.1097/PTS.0000000000000244

Source DB:  PubMed          Journal:  J Patient Saf        ISSN: 1549-8417            Impact factor:   2.844


  3 in total

1.  Melatonin alleviates angiotensin-II-induced cardiac hypertrophy via activating MICU1 pathway.

Authors:  Yi Yang; Jin Du; Rui Xu; Yang Shen; Dachun Yang; Houxiang Hu; Haifeng Pei; Yongjian Yang
Journal:  Aging (Albany NY)       Date:  2020-11-26       Impact factor: 5.682

2.  Investigation of angiotensin-I-converting enzyme (ACE) inhibitory tri-peptides: a combination of 3D-QSAR and molecular docking simulations.

Authors:  Fangfang Wang; Bo Zhou
Journal:  RSC Adv       Date:  2020-09-30       Impact factor: 4.036

3.  Positive Effect of a Pea-Clam Two-Peptide Composite on Hypertension and Organ Protection in Spontaneously Hypertensive Rats.

Authors:  Xiaopeng Sun; Min Wang; Chuanjin Xu; Shanglong Wang; Li Li; Shengcan Zou; Jia Yu; Yuxi Wei
Journal:  Nutrients       Date:  2022-09-30       Impact factor: 6.706

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.